Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Humanwell Healthcare Group Co Ltd (Humanwell Healthcare) is a pharmaceutical company that provides narcotic drugs, steroid hormones drugs, and Uyghur medicine. The company offers active pharmaceutical ingredients such as progestogen and estrogen products, androgen products, cortical hormone products and others. It also offers services for new drug research, development, clinical trials, and registration. Humanwell Healthcare offers its products in the dosage forms of injectables, capsules, oral liquids, syrup and granules. The company has its research and development center’s in the US, Germany and China. It operates in Asia, North America, Africa and Europe. Humanwell Healthcare is headquartered in Wuhan, Hubei, China.
Headquarters
China
Address
No. 666 Gaoxin Avenue, East Lake High-tech Development Zone, Wuhan, Hubei, 430075
Website
www.humanwell.com.cn
Telephone
86 27 87597232
No of Employees
17,153
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600079 (SHA)
Revenue (2024)
$3.3B
-5.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
39.5%
(2024 vs 2023)
Market Cap*
$4.6B
Net Profit Margin (2024)
XYZ
48.0%
(2024 vs 2023)
* As of and is in US$
Humanwell Healthcare Group Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Active Pharmaceutical Ingredients: | New Drug Research Services | RuiMa |
| Progestogen and Estrogen Products | Development Services | LinBingFen |
| Androgen Products | Clinical Trials Services | Guang Shi Tong |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, Wuhan Jiulong Pharmaceutical Co., Ltd. received approval from NMPA for the marketing of its Class 4 generic ibuprofen suspension. |
| 2025 | New Products/Services | In September, the company launched P2X purinoceptor 7 (P2RX7; P2X7) antagonists. |
| 2025 | New Products/Services | In February, the company developed new proteolysis targeting chimera (PROTAC) compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK-4). |
Competitor Comparison
| Key Parameters | Humanwell Healthcare Group Co Ltd | Huadong Medicine Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Jinyao Pharmaceutical Co Ltd | Guilin Sanjin Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Wuhan | Hangzhou | Shanghai | Tianjin | Guilin |
| State/Province | Hubei | Zhejiang | Shanghai | Tianjin | Guangxi |
| No. of Employees | 17,153 | 19,095 | 40,603 | 2,731 | 2,556 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Deng Weidong | Chairman | Executive Board | - | - |
| Du Wentao | General Manager; Director - Financial; Chief Financial Officer | Senior Management | - | - |
| Yin Qiang | Deputy General Manager | Senior Management | - | - |
| Liu Nanhong | Deputy General Manager; Secretary | Senior Management | - | - |
| Li Jun | Deputy General Manager | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer